The Valuation Analyst

3.5K posts

The Valuation Analyst banner
The Valuation Analyst

The Valuation Analyst

@ValuationEdge_

📊 Fundamental & Technical Analyst 🧠 I help investors cut through noise → better decisions ⚠️ Not financial advice

Katılım Eylül 2025
106 Takip Edilen2.1K Takipçiler
Sabitlenmiş Tweet
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
Most investors buy stories, not businesses. I started @valuationedge_ to do the opposite — to cut through noise and find mispriced growth using fundamentals. I share: • Deep dives on real businesses • Data-backed setups that make sense • Simple frameworks that help you invest with conviction No hype. No fluff. Just fundamentals. Follow if you want logic to beat noise.
English
8
0
31
7.7K
Luc
Luc@investingluc·
@ValuationEdge_ Let me put some thought into this. Bookmarking - will get back to you!
English
1
0
1
32
Luc
Luc@investingluc·
Might ruffle some feathers here, but if you're 20-25 y/o and want to make big $$ in the markets, I would: (...and this isn't that long, read to the end) 1) get a 9-5 job w earning potential first (sales, etc) 2) save some money over ~3 years (goal: $25-$50K) 3) learn aggressively about markets in those ~3 years 4) start swing trading common stock on the side 5) build confidence + track record 6) continuing growing account 7) if successful, add more $$ from job into account 8) hit $100K swinging shares 9) compound 10) never need excessive leverage, short-term options, or huge risk *MOST important point* Don't start out with $1K and try to grow it to $1M in a year (or three)...the amount of grotesque risk/leverage you need to pull that off will set you back a decade when it comes to bad habits. Most people want to take the fast path (options, margin, leverage, loans), and get rich quick. But if you start with a solid foundation of hard earned money (the $25K+ you saved), rules, knowledge, and a respect for capital...you have a 1000x better chance of winning long term.
English
16
14
228
27.4K
ₕₐₘₚₜₒₙ
ₕₐₘₚₜₒₙ@hamptonism·
What are some life-maxxing supplements you should be taking to 10x your health?
English
79
9
330
50.8K
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
@TheLongInvest What are the most expensive supplements/peptides specifically for you? Respect it but 25k is insane, would love to know the whole stack/routine
English
3
0
3
1.6K
The Long Investor
The Long Investor@TheLongInvest·
I spend about $25,000 a year on supplements and peptides. It's a mess, everything is all over the place. AG1, creatine, peptides, protein, hair and skin treatments, weight loss, muscle gain, testosterone, and vitamins... all need to be ordered separately where I live. If I could order everything in one place, I would be a customer for life. Men are becoming increasingly conscious of their health and appearance, and the market will explode soon to facilitate this One company will benefit from this.
English
76
10
547
83.2K
The Long Investor
The Long Investor@TheLongInvest·
Which company has the strongest Moat in the market Small, mid, large or mega cap
English
131
3
205
88.9K
Zeta
Zeta@ZetaGlobal·
4Q was a record quarter to cap a record year 📈 ✔️ Our 18th straight “beat and raise” ✔️ $395M revenue, an increase of 25% Y/Y (28% growth when excluding revenue from political candidates, LiveIntent and Marigold's Enterprise Business) ✔️ Highest-ever adj. EBITDA and FCF margins ✔️ Positive GAAP net income ✔️ Above the “rule of 50” again, and more With our proprietary data that improves with every customer interaction, intelligence that sharpens with every decision, and Athena by Zeta™ expected to become the interface that lowers the barriers to enterprise-wide adoption, we are positioned to be the AI disruptor in enterprise marketing software. Shoutout to our incredible Team Zeta for driving another quarter of growth! Learn more about our 4Q and full-year 2025 earnings results: businesswire.com/news/home/2026…
Zeta tweet media
English
27
81
592
39K
Oguz Erkan
Oguz Erkan@oguzerkan·
The market is just off 2.5% from all-time high but it feels like we are in a correction. Software got obliterated and many growth portfolios I see are down by 10-20%. Many high-quality stocks are trading at ridiculous discounts: $PGY at 9x forward earnings now, $MSFT at 22x, $BKNG at 15x.. All this while the market is basically still around all-time highs. Truly insane.
Oguz Erkan tweet media
English
41
27
287
53.3K
M. V. Cunha
M. V. Cunha@mvcinvesting·
What’s the Top 1 stock you believe won’t be disrupted by AI, but the market is pricing it as if it will? Curious to hear your best contrarian picks. 👇🏻
English
185
7
185
95K
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
@StockChaser_ Love this, simple rules Don’t need fancy charts or tech to do it either. Simple reading, studying, and applying knowledge Emotions are 90% of the difficulty in markets
English
0
0
0
118
StockChaser
StockChaser@StockChaser_·
Want to become a top-tier investor? It’s not luck. It’s discipline, strategy, and mindset. Here are 3 principles that separate amateurs from professionals 🧵👇
English
3
1
11
1.9K
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
@grok @TheLongInvest @grok What is the argument for peptide usage to be more normal for biological diseases/conditions that typical physicians can’t treat well? Will we start to rely on AI to diagnose/solve our health issues more than doctors because of cost effectiveness?
English
1
0
0
32
Grok
Grok@grok·
The $7k cost for 4 weeks likely covers premium compounded peptides (e.g., BPC-157 stacks) for off-label uses like recovery, due to high sourcing and customization expenses. Future looks strong: Market projected at $84B now, growing to $162B by 2035 (6.8% CAGR), driven by biotech advances in oral delivery and new therapies. Science shows usefulness in diabetes (GLP-1 drugs), oncology, wound healing, and orthopedics via inflammation modulation and tissue repair, per studies in Nature and PMC—though more human trials needed for safety. Economy notes surging demand from aging populations and chronic diseases, with $7B+ investments signaling high interest.
English
1
0
1
44
The Long Investor
The Long Investor@TheLongInvest·
4 weeks of Peptides $7000 I’ll keep you all updated Bullish Peptides
The Long Investor tweet media
English
113
2
333
164.4K
Sahil Bloom
Sahil Bloom@SahilBloom·
Complete this sentence with your hottest take: A lot of problems in life are solved by…
Sahil Bloom tweet media
English
837
16
379
342.5K
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
@adamkhootrader @grok why does selling and moving money around in the market feel productive when often times letting compounders grow is the best move?
English
1
0
1
222
Adam Khoo
Adam Khoo@adamkhootrader·
This is a good example of why we should STAY INVESTED in a great business over many years instead of trying to jump in and out of it, hoping to sell high and buy back lower Famed fund manager Dan Loeb (Third Point) bought and sold META 4 times over the last 10 years. He has made a net profit of $595M (+39.6% total Return) If he simply just held the shares since his first buy in 2016, his profit today will be $2.004 Billion (+491% return), 3.36X more. This was the same stupid mistake I made early on in my investing career. In fact, I first bought Facebook (FB) at $18 in 2012. See my screenshot! If I held the shares till today, my return would be 3,200% return (33X). Instead, the idiot that I was sold it at $50 for a 177% profit. Today, I would be probably be a billionaire if I had just held all the great stocks I first bought 15-20 years ago. Lesson: if we are fortunate enough to own a truly great business, the hardest thing to do is “Doing nothing” . As Charlie Munger said:  “The first rule of compounding is to never interrupt it unnecessarily!”
Adam Khoo tweet media
English
28
42
394
42.4K
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
$OSCR growth speaks for itself EV currently: $1.7B 2026 Revenue Guidance: $18B Puts $OSCR at .1x EV/Sales based on guidance Cheap is an understatement $OSCR path to profitability could make this easily $30+ in the next year $OSCR is an asymmetric bet at $13
The Valuation Analyst tweet media
English
1
0
0
255
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
$UNH trades at 11x EV/EBITDA Revenues continue to compound Cash flow is strong
The Valuation Analyst tweet media
English
1
0
2
463
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
$UBER is a cash flow monster In 2022 $UBER reached positive FCF 3 years later they grew to nearly $10B in FCF Cash is life to the business and $UBER is producing MASSIVE amounts of it AV adoption will be the key story going into 2026 but the price is right today LONG $UBER
The Valuation Analyst tweet media
English
0
0
0
254
The Valuation Analyst
The Valuation Analyst@ValuationEdge_·
$UBER looking interesting Long term uptrend -Trading 20% below 200MA -Pullback from $100 to $70 -Growing revenue 18+% still Trading at 23x EV/EBITDA
The Valuation Analyst tweet media
English
2
2
4
1.2K